Idorsia Ltd has issued the invitation to its Annual General Meeting (AGM) of Shareholders, scheduled for Wednesday, May 28, 2025, at the Congress Center, Messe Basel, Switzerland. The meeting will commence at 09.00 CEST and will focus on approving the Annual Report for the year ending December 31, 2024.

Jean-Paul Clozel, Chairman of the Board of Idorsia, expressed his gratitude to the Idorsia team and Board members for their dedication. He also announced that Dr. Sophie Kornowski will not be standing for re-election due to personal reasons, while all other Board members will seek re-election. Amendments to the Articles of Association regarding share capital are proposed to maintain financial flexibility.

The invitation to the AGM was published in the Swiss Official Gazette of Commerce and distributed to shareholders. The Annual Report, including the Business Report, Governance Report, Compensation Report, Sustainability Report, and Financial Report, is available at www.idorsia.com/agm. Shareholders must be registered by May 19, 2025, at 17:00 CEST to attend and vote.

The AGM agenda includes:

1. Annual reporting 2024, including votes on the Annual Report, Consolidated Financial Statements, Statutory Financial Statements, and consultative votes on the Compensation and Sustainability Reports.
2. Appropriation of available earnings.
3. Discharge of the Board of Directors and the Executive Committee.
4. Amendments to the Articles of Association regarding share capital, including increasing conditional share capital and amending the Capital Range.
5. Board elections, including re-election of the Board of Directors, the Chair, and members of the Nominating, Governance & Compensation Committee.
6. Votes on Board and Executive Committee compensation for the 2025–2026 term and 2026, respectively.
7. Re-election of the Independent Proxy.
8. Re-election of the statutory auditors.

Idorsia Ltd is a biopharmaceutical company headquartered near Basel, Switzerland. It focuses on discovering, developing, and commercializing transformative medicines. Noteworthy is QUVIVIQ™ (daridorexant), an insomnia treatment. The company is listed on the SIX Swiss Exchange (ticker symbol: IDIA). Contact information for Investor & Media Relations is provided for further inquiries.

The information provided includes forward-looking statements subject to risks, uncertainties, and assumptions. Actual results may vary materially from anticipated results due to various factors.